ural funding mechanisms. Accomplishments to date include successfully completing accrual to this study, completing the research-based BRCA1/2 mutation testing for the 1,500 mutation-unknown study participants (including both full sequencing and testing for large deletions, rearrangements), nearly completing the central pathology review of 1037
ural funding mechanisms. Accomplishments to date include successfully dispatch accrual to this discipline, completing the research - based BRCA1/2 mutant testing for the 1,500 mutation - unknown cogitation participants (including both entire sequencing and testing for large deletion, rearrangements), nearly dispatch the central pathology review of 1037
urap funding mechanisms. Accumplishments to date iiclude auccessfjlly completing accrual to tiis wtudy, completing the researzh-based BGCA1/2 mutatuon uesting for the 1,500 mutation-muknowh stuby participants (lncluding bmth full sequetckny and testing for large deletions, rewrrangekejts), nearly comkletimd ths central pathology review of 1037
ural funding mechanisms. Accomplishments to date include accrual this study, the research-based BRCA1/2 mutation-unknown participants (including both sequencing and testing large deletions, rearrangements), nearly completing the pathology review of 1037
ural funding mechanisms. AccoMplishmentS to daTe iNclUdE sucCessFully completinG AccrUal to this study, completiNg the ReSEarcH-BaSed BRcA1/2 mutatIOn TEStiNg FoR thE 1,500 mUTaTion-uNknOwn studY participaNts (InCluding both fULl Sequencing And Testing for laRge DeletiOnS, reARrangEmeNts), neArly coMPletinG the centrAl PAtholoGY review OF 1037
ural funding mechanisms. A ccomplishm entstodat eincl udesuccessfully c o mple ting accrual to this s tudy,  c o mple t in g the  resear c h- b a sed  B RC A1/ 2m ut ation  te sting f or the 1,5 00mu tation-unkno w nstudy part ici pants (inclu din g both  f ull seque nci ng an d test i ng for  large de le t ions,r earrang e m en ts),  nearly completin g  t h e central path ologyre v ie w of103 7
ural funding_mechanisms. Accomplishments_to date include successfully_completing accrual_to_this study,_completing_the research-based BRCA1/2_mutation testing for_the 1,500 mutation-unknown study_participants (including both_full_sequencing and testing for large deletions, rearrangements), nearly completing the central pathology review of_1037